Skip to main content
. 2023 Jul 22;16:79. doi: 10.1186/s13045-023-01470-0

Fig. 4.

Fig. 4

Expansion of HD-CAR-1 CARTs. A Expansion of CARTs in the peripheral blood (PB) of individual HD-CAR-1 patients (n = 13) assessed by single-copy gene duplex quantitative PCR (SCG-DP-PCR) [19] after CART administration and up to end of study (EOS) at day 90. B Median expansion of CARTs according to administered CART dose levels (DL; DL1: 1 × 106 CARTs/m2, DL2: 5 × 106 CARTs/m2, DL3: 20 × 106 CARTs/m2, DL4: 5 × 107 CARTs/m2). C Maximum CART copies (cmax) within 28 days after CART administration and clinical response at EOS (data of UPN#8 not shown due to progressive disease on day 23 after CARTs). Median (cmax) 22.350 CART/µg DNA PBMC. CR complete remission, d day, DL dose level, MRD minimal residual disease, PBMC peripheral blood mononuclear cell, PD progressive disease, UPN unique patient number